Clinical Trial Update: Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adalimumab for induction of remission in Crohn's disease has completed enrollment/status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED